Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 134


Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodies.

Yang G, Holl TM, Liu Y, Li Y, Lu X, Nicely NI, Kepler TB, Alam SM, Liao HX, Cain DW, Spicer L, VandeBerg JL, Haynes BF, Kelsoe G.

J Exp Med. 2013 Feb 11;210(2):241-56. doi: 10.1084/jem.20121977. Epub 2013 Jan 28.


Common tolerance mechanisms, but distinct cross-reactivities associated with gp41 and lipids, limit production of HIV-1 broad neutralizing antibodies 2F5 and 4E10.

Chen Y, Zhang J, Hwang KK, Bouton-Verville H, Xia SM, Newman A, Ouyang YB, Haynes BF, Verkoczy L.

J Immunol. 2013 Aug 1;191(3):1260-75. doi: 10.4049/jimmunol.1300770. Epub 2013 Jul 3.


Envelope deglycosylation enhances antigenicity of HIV-1 gp41 epitopes for both broad neutralizing antibodies and their unmutated ancestor antibodies.

Ma BJ, Alam SM, Go EP, Lu X, Desaire H, Tomaras GD, Bowman C, Sutherland LL, Scearce RM, Santra S, Letvin NL, Kepler TB, Liao HX, Haynes BF.

PLoS Pathog. 2011 Sep;7(9):e1002200. doi: 10.1371/journal.ppat.1002200. Epub 2011 Sep 1.


Interactions of HIV-1 antibodies 2F5 and 4E10 with a gp41 epitope prebound to host and viral membrane model systems.

Veiga AS, Pattenden LK, Fletcher JM, Castanho MA, Aguilar MI.

Chembiochem. 2009 Apr 17;10(6):1032-44. doi: 10.1002/cbic.200800609.


Chemically modified peptides based on the membrane-proximal external region of the HIV-1 envelope induce high-titer, epitope-specific nonneutralizing antibodies in rabbits.

Venditto VJ, Wieczorek L, Molnar S, Teque F, Landucci G, Watson DS, Forthal D, Polonis VR, Levy JA, Szoka FC Jr.

Clin Vaccine Immunol. 2014 Aug;21(8):1086-93. doi: 10.1128/CVI.00320-14. Epub 2014 May 28.


Cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody that recognizes a novel conformational epitope on gp41 and lacks reactivity against self-antigens.

Zhang MY, Vu BK, Choudhary A, Lu H, Humbert M, Ong H, Alam M, Ruprecht RM, Quinnan G, Jiang S, Montefiori DC, Mascola JR, Broder CC, Haynes BF, Dimitrov DS.

J Virol. 2008 Jul;82(14):6869-79. doi: 10.1128/JVI.00033-08. Epub 2008 May 14.


N-terminal residues of an HIV-1 gp41 membrane-proximal external region antigen influence broadly neutralizing 2F5-like antibodies.

Li D, Liu J, Zhang L, Xu T, Chen J, Wang L, Zhao Q.

Virol Sin. 2015 Dec;30(6):449-56. doi: 10.1007/s12250-015-3664-6. Epub 2015 Dec 21.


Analysis of the human immunodeficiency virus type 1 gp41 membrane proximal external region arrayed on hepatitis B surface antigen particles.

Phogat S, Svehla K, Tang M, Spadaccini A, Muller J, Mascola J, Berkower I, Wyatt R.

Virology. 2008 Mar 30;373(1):72-84. Epub 2007 Dec 26.


Heterologous epitope-scaffold prime:boosting immuno-focuses B cell responses to the HIV-1 gp41 2F5 neutralization determinant.

Guenaga J, Dosenovic P, Ofek G, Baker D, Schief WR, Kwong PD, Karlsson Hedestam GB, Wyatt RT.

PLoS One. 2011 Jan 26;6(1):e16074. doi: 10.1371/journal.pone.0016074.


Structure-guided alterations of the gp41-directed HIV-1 broadly neutralizing antibody 2F5 reveal new properties regarding its neutralizing function.

Guenaga J, Wyatt RT.

PLoS Pathog. 2012;8(7):e1002806. doi: 10.1371/journal.ppat.1002806. Epub 2012 Jul 19.


The broadly neutralizing anti-human immunodeficiency virus type 1 4E10 monoclonal antibody is better adapted to membrane-bound epitope recognition and blocking than 2F5.

Huarte N, Lorizate M, Maeso R, Kunert R, Arranz R, Valpuesta JM, Nieva JL.

J Virol. 2008 Sep;82(18):8986-96. doi: 10.1128/JVI.00846-08. Epub 2008 Jul 2.


An affinity-enhanced neutralizing antibody against the membrane-proximal external region of human immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10.

Nelson JD, Brunel FM, Jensen R, Crooks ET, Cardoso RM, Wang M, Hessell A, Wilson IA, Binley JM, Dawson PE, Burton DR, Zwick MB.

J Virol. 2007 Apr;81(8):4033-43. Epub 2007 Feb 7.


Association of variations of NAb 2F5 and 4E10 epitopes and disease progression in Chinese antiretroviral treatment-naïve patients infected with HIV-1 clade B'.

Zhang XL, Han XX, Dai D, Bao MJ, Xu DB, Zhang ZN, Wang YN, Zhao M, Bice T, Jiang YJ, Shang H.

Chin Med J (Engl). 2010 Dec;123(23):3406-11.


Anti-HIV-1 antibodies 2F5 and 4E10 interact differently with lipids to bind their epitopes.

Franquelim HG, Chiantia S, Veiga AS, Santos NC, Schwille P, Castanho MA.

AIDS. 2011 Feb 20;25(4):419-28. doi: 10.1097/QAD.0b013e328342ff11.


A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1.

Stiegler G, Kunert R, Purtscher M, Wolbank S, Voglauer R, Steindl F, Katinger H.

AIDS Res Hum Retroviruses. 2001 Dec 10;17(18):1757-65.


Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope.

Ofek G, Tang M, Sambor A, Katinger H, Mascola JR, Wyatt R, Kwong PD.

J Virol. 2004 Oct;78(19):10724-37.


Simian immunodeficiency virus engrafted with human immunodeficiency virus type 1 (HIV-1)-specific epitopes: replication, neutralization, and survey of HIV-1-positive plasma.

Yuste E, Sanford HB, Carmody J, Bixby J, Little S, Zwick MB, Greenough T, Burton DR, Richman DD, Desrosiers RC, Johnson WE.

J Virol. 2006 Mar;80(6):3030-41.


Membrane association and epitope recognition by HIV-1 neutralizing anti-gp41 2F5 and 4E10 antibodies.

Sánchez-Martínez S, Lorizate M, Katinger H, Kunert R, Nieva JL.

AIDS Res Hum Retroviruses. 2006 Oct;22(10):998-1006.


Supplemental Content

Support Center